Consider pharmacotherapy for appropriate patients with obesity1,2

Pharmacotherapy can play an important role in weight management by supplementing healthy eating and physical activity.1,2

The principles of pharmacology

Lifestyle modifications such as healthy eating and increased physical activity are foundational to obesity management. Sometimes, however, they are not enough to achieve long-term health benefits, and a prescription weight-management medication (PWMM) is needed.1-3

For appropriate patients, pharmacological treatments are part of a comprehensive approach to long-term weight management.2

3 guiding principles3

Principles to follow when considering pharmacotherapy for patients with obesity:

Icon of the number 1

Reinforce patient efforts

Pharmacotherapy is meant to reinforce a patient’s lifestyle efforts, not replace them

Icon of the number 2

Understand side effects

Both health care professionals and patients should be familiar with the medication and its potential side effects and contraindications

Icon of the number 3

Every patient is different

If clinically meaningful weight loss (≥5%) is not achieved after 3-4 months, a new treatment plan should be considered

DIAGNOSING OBESITY

Obesity patient
example profiles

Review example profiles of patients with obesity who may be similar to patients you see in your own practice.

SEE PROFILES

Most patients living with obesity are not able to achieve and maintain a healthy weight with healthy eating and increased physical activity alone1

Some pharmacological treatments may benefit patients who:

  • Have tried lifestyle changes but can’t reach a healthier weight
  • Are regaining weight after losing it
  • Have a BMI of ≥27 kg/m2 and a weight-related comorbidity
  • Have a BMI that is ≥30 kg/m2

Current medications approved for long-term use should be offered to patients when potential benefits outweigh the risks.1

Adding pharmacotherapy to a lifestyle plan may improve weight-loss results4*

Graph depicting differences in mean percentage weight reduction over 72 weeks between anti-obesity medication users and non-users

*Data from a retrospective study evaluating the impact of PWMM over 72 weeks in 129 adults with obesity (>30 kg/m²) participating in a comprehensive precision weight-loss program.4

BMI, body mass index.

INITIATING A PLAN

Achieve continued weight management success

See How

DIAGNOSING OBESITY

Start the conversation on weight management

TIPS TO START TALKING

References:

1. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203.

2. Pilitsi E, Farr OM, Polyzos SA, et al. Pharmacotherapy of obesity: available medications and drugs under investigation. Metabolism. 2019;92:170-192.



3. Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet. 2016;387(10031):1947-1956.

4. Safavi R, Lih A, Kirkpatrick S, Haller S, Bailony MR. Impact of anti-obesity medication initiation and duration on weight loss in a comprehensive weight loss programme. Obes Sci Pract. 2019;5(5):468-478.

Continue

You are now leaving the Novo Nordisk US affiliate site. Novo Nordisk is not responsible for the content of the site you are about to visit.

Continue